PharmaCyte Biotech is a development-stage biotech with no commercial products or revenue. Its core program is a cell-based cancer therapy targeting locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) in patients who no longer respond to standard chemotherapy. The therapy uses Cell-in-a-Box, a proprietary encapsulation technology that places genetically engineered human cells inside small cellulose capsules (CypCaps), which are implanted near a pancreatic tumor via catheter. The encapsulated cells convert a chemotherapy prodrug into its active form locally, near the tumor, with the goal of targeted drug activation and reduced systemic toxicity. PharmaCyte has received Orphan Drug Designation from both the FDA and EMA. The company filed an IND in 2020, but the FDA placed it on clinical hold due to manufacturing, non-clinical data, and technical deficiencies; the hold remains in place. PharmaCyte funds operations through equity issuances and plans to either commercialize its therapy or license it to a larger pharma company upon approval. The company's patents have all expired, leaving it reliant on trade secrets held by its licensor, SG Austria. PharmaCyte has only two full-time employees, depends on a single manufacturer (Austrianova) for CypCaps production, and has curtailed R&D spending pending a strategic review of its programs and its relationship with SG Austria.